Importantly, the combination of verteporfin and DDP not only enhanced the immune response but also reduced immune exhaustion in the tumor microenvironment, indicating YAP1 as a therapeutic target to overcome immune suppression during chemotherapy. The gene discussed is YAP1; the disease is neoplasm.